10x Genomics (TXG) Stock: Citi Downgrade, AI Partnerships and 2026 Forecast After December 11 Sell-Off
10x Genomics shares fell over 6% to the mid-$16 range on December 11, 2025, after Citigroup downgraded the stock from Buy to Neutral, maintaining an $18 price target. The company’s market cap stands near $2.2 billion. Despite the drop, shares remain up more than 20% year to date. Analyst consensus now leans Hold, with average 12-month price targets around $15–17.
